Risk assessment framework
A structured, safety-focused reference for reviewing the medical, medication, laboratory, cardiac, and withdrawal considerations that may matter before ibogaine exposure.
Statement of scope
Screening is a risk-assessment process, not a clearance certificate. A checklist can organize questions and tests, but it cannot establish that ibogaine is safe for any individual or remove the need for qualified clinical judgment.
This page is limited to preparation and screening domains. It is not a dosing or administration protocol, does not provide unsupervised instructions, and does not imply that passing screening eliminates cardiac, psychiatric, toxicologic, or other risks. For broader context, the independent preparation overview places this checklist alongside the questions people commonly bring to an initial review.
Ibogaine has been associated with cardiac rhythm concerns, particularly where QT interval prolongation or interacting factors are present. The FDA’s drug-interaction framework is a useful high-level reminder that metabolism and medication combinations require careful review rather than assumptions.
Three screening domains
Document cardiac history, syncope, palpitations, known rhythm disorders, structural heart disease, hepatic or renal disease, seizure history, psychiatric history, and prior adverse reactions to medicines or substances.
Symptoms or history suggestive of cardiovascular disease should prompt a more complete assessment; the American Heart Association’s overview of arrhythmia explains why disturbances in rhythm warrant attention rather than casual interpretation.
Review prescribed medicines, over-the-counter products, supplements, recent substance use, and medicines taken intermittently. The review should identify products that may affect QTc, electrolytes, sedation, seizure threshold, or metabolic pathways.
Include antidepressants, antipsychotics, stimulants, opioid-related medicines, antibiotics, antiemetics, antihistamines, diuretics, and herbal or concentrated supplement products where relevant. A complete list is more useful than a partial memory-based account.
Assess pregnancy possibility, hydration and nutrition concerns, vomiting or diarrhea, acute illness, recent overdose, intoxication, and withdrawal risk. These conditions can materially affect laboratory findings, rhythm vulnerability, and the ability to interpret a screening result.
Where opioid exposure is relevant, overdose and withdrawal assessment should distinguish immediate safety issues from longer-term planning; screening considerations across changing conditions can help frame why timing and current status matter.
Core tests and records
Screening commonly combines history with objective measures. Results should be reviewed in context, including medicines, recent substance exposure, acute symptoms, and whether a value could reflect a correctable or urgent condition.
Cardiac focus
A baseline ECG should be obtained and interpreted with a documented QTc value rather than a general statement that the tracing is “normal.” Review should consider rate, rhythm, conduction findings, T-wave changes, prior ECGs when available, and the limitations of automated readings.
Abnormal QTc results, a history of fainting or unexplained palpitations, known arrhythmia, family history suggestive of inherited rhythm syndromes, or use of QTc-affecting medicines should prompt appropriately qualified cardiac review. The cardiac safety guide provides a companion outline of the questions that make this part of screening more specific.
Electrolytes are part of the same safety picture. Potassium, magnesium, and calcium abnormalities can affect electrical stability, while dehydration, gastrointestinal losses, diuretics, or acute illness can make one set of values an incomplete picture of current risk.
Frameworked methodology
Checklist items work best when they lead to an explicit decision: information is complete, clarification is needed, a specialist should assess the finding, or exposure should not be considered.
Record cardiovascular, hepatic, renal, neurologic, psychiatric, pregnancy-related, and substance-use history alongside current symptoms and prior records where available.
Compare prescriptions, over-the-counter products, supplements, and recent substances against possible QTc effects, metabolic interactions, sedation, seizure threshold, and withdrawal implications.
Consider ECG with QTc, electrolyte testing, liver and kidney function tests, pregnancy testing when applicable, and toxicology in the context of history rather than as isolated pass-or-fail results.
Arrange appropriate specialist or urgent assessment when findings suggest cardiac, organ-function, psychiatric, overdose, intoxication, or withdrawal risk. Do not treat uncertainty as reassurance.
Clarifying questions
No. A result may be reassuring in a narrow context, but it does not eliminate risk or predict every response. Screening identifies known concerns, missing information, and findings that may call for more assessment or exclusion.
Products outside a prescription list can still affect cardiac rhythm, electrolyte balance, sedation, or metabolic pathways. A complete review helps prevent a false sense of safety based on incomplete information.
Cardiac symptoms or ECG findings, prolonged QTc, substantial electrolyte abnormalities, organ-function concerns, complex psychiatric history, pregnancy-related questions, and unstable intoxication or withdrawal states warrant escalation rather than a simple checklist decision.
No. This resource does not give dosing, administration, or unsupervised preparation instructions. Its purpose is to organize risk-assessment questions for people researching ibogaine preparation and screening.
Independent resource
Use this checklist to identify what should be documented, tested, interpreted, and escalated—not as a substitute for medical assessment or an assurance that risk has been resolved.